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Abstract
Background: The discovery of microRNA (miRNA) has revealed a novel type of regulatory control for gene expression.
Increasing evidence suggests that miRNA regulates chondrocyte, osteoblast, and osteoclast differentiation and function,
indicating miRNA as key regulators of bone formation, resorption, remodeling, and repair. We hypothesized that the
functions of certain miRNAs and changes to their expression pattern may play crucial roles during the process of
fracture healing.
Methods: Standard healing fractures and unhealing fractures produced by periosteal cauterization at the fracture site
were created in femurs of seventy rats, with half assigned to the standard healing fracture group and half assigned to
the nonunion group. At post-fracture days 3, 7, 10, 14, 21, and 28, total RNA including miRNA was extracted from the
newly generated tissue at the fracture site. Microarray analysis was performed with miRNA samples from each group on
post-fracture day 14. For further analysis, we selected highly up-regulated five miRNAs in the standard healing fracture
group from the microarray data. Real-time PCR was performed with miRNA samples at each time point above mentioned
to compare the expression levels of the selected miRNAs between standard healing fractures and unhealing fractures and
investigate their time-course changes.
Results: Microarray and real-time polymerase chain reaction (PCR) analyses on day 14 revealed that five miRNAs,
miR-140-3p, miR-140-5p, miR-181a-5p, miR-181d-5p, and miR-451a, were significantly highly expressed in standard
healing fractures compared with unhealing fractures. Real-time PCR analysis further revealed that in standard healing
fractures, the expression of all five of these miRNAs peaked on day 14 and declined thereafter.
Conclusion: Our results suggest that the five miRNAs identified using microarray and real-time PCR analyses may play
important roles during fracture healing. These findings provide valuable information to further understand the molecular
mechanism of fracture healing and may lead to the development of miRNA-based tissue engineering strategies to
promote fracture healing.
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Background
There are more than 18.3 million fractures treated in the
United States annually [1]. It has been estimated that 5–10
% of fractures have delayed or disrupted healing, resulting
in significant morbidity and tremendous loss of productiv-
ity and income [2]. Impairment of fracture healing causes
not only individual but also economic damage. In the
United States, in 2007, fracture patients who required
hospitalization produced over $29 billion in hospital costs
[1]. Thus, enhancing quality and/or speed of fracture heal-
ing would be of substantial benefit to patients and would
reduce the social burden. Such improvement can be real-
ized through a better understanding of fracture healing.
Hence, by means of in vitro and in vivo experiments, con-
siderable efforts have been made to elucidate the molecu-
lar mechanisms of fracture healing [3–5].
The recent discovery of microRNA (miRNA) has re-
vealed a novel type of regulatory control for gene expres-
sion. miRNA is a class of small non-coding RNA that
regulates gene expression by binding the 3′-untranslated
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region (3′-UTR) of target messenger RNAs (mRNAs),
leading to inhibition of translation or mRNA degradation
[6]. miRNA plays key roles in biological processes, such as
cell growth, differentiation, and organ development [7].
Furthermore, miRNA has been associated with human
disease, including cancer [8], and, therefore, have potential
as novel therapeutic targets. In the field of skeletal biology,
several in vitro and a few in vivo studies suggest that
miRNA regulates chondrocyte, osteoblast, and osteoclast
differentiation and function, indicating that miRNA is a
key regulator of bone formation, resorption, remodeling,
and repair [9, 10]. miRNA has also been implicated in
bone-related disorders, such as osteoporosis [10, 11].
It has recently been reported that miRNAs may con-
tribute to fracture healing. Murata et al. demonstrated
that inhibition of miR-92a enhances fracture healing in
mice [12]. Seeliger et al. profiled miRNAs in bone tissue
from patients with osteoporotic fractures and identified
five miRNAs, miR-21, miR-23a, miR-24, miR-100, and
miR-125b that are highly associated with osteoporotic
fractures [13]. With regard to fracture nonunion, we re-
cently profiled miRNAs in nonunion of the rat femur and
identified five miRNAs, miR-31a-3p, miR-31a-5p, miR-
146a-5p, miR-146b-5p, and miR- 223-3p that were associ-
ated with the development of nonunion [14]. However, the
role of miRNAs during fracture healing is not well under-
stood. The elucidation of miRNA expression changes dur-
ing the process of fracture healing may provide more
accurate insight into the molecular pathways that regulate
bone repair and regeneration and may inform therapeutic
intervention to accelerate fracture healing.
We hypothesized that the functions of certain miRNAs
and changes to their expression pattern may play crucial
roles during the process of fracture healing. The purpose
of this study was to examine miRNA expression profiles
during standard fracture healing of the rat femur by
microarray analysis and to elucidate the dynamic expres-
sion patterns of highly expressed miRNAs during frac-
ture healing.
Methods
Femoral fracture animal model
Twelve-week-old male Sprague–Dawley rats (CLEA Japan,
Tokyo, Japan) weighing 382.7 ± 6.3 g were used in this
study. All animal procedures were performed under the
approval and guidance of the Animal Care and Use Com-
mittee of Kobe University Graduate School of Medicine.
Animals were randomized to receive either a surgical
treatment that produces a standard, closed femoral shaft
fracture that is known to successfully heal or an unhealing
femoral shaft fracture (Fig. 1). The details of these proce-
dures have been previously described [15, 16]. Briefly, a
1.2-mm diameter K-wire was inserted retrograde into the
right femoral intramedullary canal and a closed transverse
femoral shaft fracture was produced in all animals using a
three-point bending apparatus with a drop weight [15].
Hypodermic injection of buprenorphine provided postop-
erative analgesia. To create unhealing femoral fractures,
the fractured site was then exposed through a lateral
approach and the periosteum was cauterized circumferen-
tially for a distance of 2 mm on each side of the fracture.
This experimental model reproducibly leads to an atro-
phic nonunion at 8 weeks after surgery [16]. Unprotected
weight bearing was allowed post-operatively. Seventy ani-
mals were used in this study, with half assigned to the
standard healing fracture group and half assigned to the
unhealing fracture group. Five animals from each group
were euthanized on post-fracture day 14 for microarray
analysis and five animals from each group were eutha-
nized on post-fracture days 3, 7, 10, 14, 21, and 28 for
real-time polymerase chain reaction (PCR) analysis. These
time points were selected based on our previous experi-
ments [17, 18]. At these time points, the newly generated
tissues, that is, the fracture callus for the standard healing
fractures and the fibrous tissue surrounding the fracture
site for the unhealing fractures, were harvested. Following
euthanasia, the surrounding muscles were cleanly dis-
sected away from the callus or fibrous tissue generated at
the fracture site. The external callus or fibrous tissue
Fig. 1 Radiographs of the standard healing fractures (a and b) and unhealing fractures (c and d) obtained immediately post-fracture (a and c)
and at post-fracture day 28 (b and d)
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generated at the fracture site was excised circumferentially
from the underlying intact cortical bone by dissection with
a scalpel and rongeur. Care was taken to harvest only
newly generated tissue and to not include any underlying
intact bone. Because there was no organized callus on
post-fracture day 3, the tissue harvested from each model
was the fracture hematoma existing at the fracture site.
miRNA microarray analysis
For miRNA microarray analysis, tissues were harvested on
post-fracture day 14 and stored in RNAlater (Ambion,
Austin, TX, USA). Total RNA, including miRNA, was ex-
tracted from the tissue specimens of five different animals
in each group using a miRCURY RNA Isolation Kit-Tissue
(Exiqon, Vedbaek, Denmark). The quality of the total RNA
was verified using an Agilent 2100 Bioanalyzer profile
(Agilent Technologies, Santa Clara, CA, USA). One micro-
gram of total RNA from sample and reference RNAs was
labeled with Hy3 and Hy5 fluorescent labels, respectively,
using a miRCURY LNA microRNA Hi-Power Labeling Kit
(Exiqon). The Hy3-labeled samples and a Hy5-labeled ref-
erence RNA sample were mixed pair-wise and hybridized
to a miRCURY LNA Array, version 6th Generation (Exi-
qon), which contains capture probes targeting all human,
mouse, and rat miRNAs registered in miRBASE version
16.0. Labeling, hybridization, washing, and scanning were
performed following the instructions of the manufacturers.
Data analysis was carried out using Feature Extraction
10.7.3.1 (Agilent Technologies).
Quantitative real-time PCR analysis
For further analysis of the array results, we selected miR-
NAs that were highly up-regulated in the standard heal-
ing fracture group. To compare the expression levels of
the selected miRNAs between standard healing fractures
and unhealing fractures and to investigate their changes
in expression over time in standard healing fractures,
real-time PCR was performed on RNA from tissue speci-
mens collected on post-fracture days 3, 7, 10, 14, 21, and
28 (n = 5 in each group at each time point). Tissue spec-
imens were homogenized with a T 18 ULTRA-TURRAX
homogenizer (IKA Werke, Staufen, Germany) and total
RNA, including miRNAs, was extracted using a miRCURY
RNA Isolation Kit-Tissue. RNA used for real-time PCR as-
says did not include any of the RNA used in the micro-
array assay. Total RNA was reverse transcribed into
single-strand cDNA using the miRCURY LNA Universal
RT microRNA PCR kit (Exiqon). Real-time PCR analysis
was performed in duplicate with a StepOne Sequence De-
tector (Applied Biosystems, Branchburg, NJ, USA), using
SYBR Green master mix and microRNA LNA PCR primer
sets (both from Exiqon). U6 was used as an internal con-
trol to normalize differences in miRNA levels in each sam-
ple. The relative abundance of each miRNA was calculated
using the comparative ΔΔCT method, and is presented as
the fold change relative to levels in the post-fracture day 3,
standard healing fracture sample.
Statistical analysis
All the quantitative data are presented as means ± stand-
ard errors. The values of standard healing fractures and
unhealing fractures were compared at each time point
using the Mann–Whitney U-test. The Kruskal–Wallis test
and Mann–Whitney U-test with Bonferroni correction
were used to compare between time points in the stand-
ard healing fractures group. A p-value of < 0.05 was de-
fined as statistically significant.
Results
miRNA microarray analysis
Using a miRNA microarray approach, we tested the ex-
pression of 680 rat miRNAs. There were 317 miRNAs
that were expressed more highly in standard healing
fractures compared with unhealing fractures. From these
317 miRNAs, those that were highly up-regulated were
extracted by filtering with a fold change of > 2.0, a low
coefficient variation (<50 %), and a high Hy3 signal
(>10). With these criteria we identified eight miRNAs:
miR-140-3p, miR-140-5p, miR-181a-5p, miR-181d-5p,
miR-208b-3p, miR-451a, miR-743b-5p, and miR-879-3p
(Table 1). The microarray data have been deposited in
the NCBI’s Gene Expression Omnibus (GEO) and are
accessible through GEO series accession no. GSE 55088.
Real-time PCR analysis
The five most highly expressed miRNAs that were con-
served between rat and human were selected from the
microarray data. We selected miRNAs that were con-
served between rat and human so that our results can re-
flect standard fracture healing in humans. These miRNAs
were miR-140-3p, miR-140-5p, miR-181a-5p, miR-181d-
5p, and miR-451a. Validation by real-time PCR analysis
confirmed that the expression of all five miRNAs was sig-
nificantly higher in standard healing fractures compared
with unhealing fractures on post-fracture day 14 in a man-
ner consistent with the data from the microarray analysis
Table 1 Highly up-regulated miRNAs in standard healing fractures
compared with expression in unhealing fractures on post-fracture
day 14
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(Fig. 2, 3; p < 0.05). In addition, we followed the dy-
namic expression patterns of these five miRNAs, as
described below.
miR-140-3p and miR-140-5p
The expression of miR-140-3p and -5p was significantly
higher in standard healing fractures than in unhealing
fractures on post-fracture days 7, 10, and 14 (p < 0.05)
(Figs. 2a, b and 3a, b). In standard healing fractures, ex-
pression of both increased with time until day 14, and
then declined. There were significant differences be-
tween days 3 and 7, 7 and 10, 10 and 14, 14 and 21, and
21 and 28 in the expression of miR-140-3p (p < 0.05),
whereas there were significant differences between days
7 and 10, 10 and 14, 14 and 21, and 21 and 28 in the ex-
pression of miR-140-5p (p < 0.05).
miR-181a-5p
The expression of miR-181a-5p was significantly higher
in standard healing fractures than in unhealing frac-
tures on post-fracture days 7, 10, 14, and 21 (p < 0.05)
(Figs. 2c and 3c). Expression in standard healing frac-
tures peaked on day 14 and then declined with time.
There were significant differences between days 7 and
10, 10 and 14, 14 and 21, and 21 and 28 (p < 0.05).
miR-181d-5p
The expression of miR-181d-5p was significantly higher in
standard healing fractures than in unhealing fractures on
post-fracture days 3, 10, and 14 (p < 0.05) (Fig. 2d and 3d).
The expression in standard healing fractures was declined
on day 7, then increased until day 14, and then declined
with time. There were significant differences between days
3 and 7, 7 and 10, 10 and 14, and 14 and 21 (p < 0.05).
miR-451a
The expression of miR-451a was significantly higher in
standard healing fractures compared with that in unheal-
ing fractures on post-fracture days 14 and 28 (p < 0.05)
(Figs. 2e and 3e). In standard healing fractures, expres-
sion was significantly declined on day 7, then increased
until day 14, then again declined on day 21, and then
Fig. 2 Expression of miR-140-3p (a), miR-140-5p (b), miR-181a-5p (c), miR-181d-5p (d), and miR-451a (e) in standard healing fractures (solid bars)
and in unhealing fractures (blank bars) on post-fracture days 3 and 7, as analyzed by real-time PCR. All graphs show the fold change in expression
when expression in the standard healing fracture on day 3 was normalized as 1. Values are the mean ± standard error (n = 5 in each group at
each time point). *p < 0.05 for indicated groups. a, p < 0.05 versus values on day 3 in standard healing fracture; b, p < 0.05 versus values on day
7 in standard healing fracture; c, p < 0.05 versus values on day 10 in standard healing fracture; d, p < 0.05 versus values on day 21 in standard
healing fracture; e, p < 0.05 versus values on day 28 in standard healing fracture
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again increased on day 28. There were significant differ-
ences between days 3 and 7, 7 and 10, 10 and 14, and 14
and 21, and 21 and 28 (p < 0.05).
Discussion
miRNAs play critical roles in many physiological and
pathophysiological process [6], and have recently emerged
as key regulators in bone metabolism, development and
repair, and in bone-related disease [10–13]. To better
understand the underlying physiological mechanisms of
fracture healing, the present study focused on miRNA ex-
pression profiles in standard healing fractures of the rat
femur. This study identified, for the first time, that five
miRNAs, miR-140-3p, miR-140-5p, miR-181a-5p, miR-
181d-5p, and miR-451a, are highly expressed with dy-
namic expression patterns in standard healing fractures in
rats. These findings potentially give insight into miRNA
regulation during fracture healing.
Fracture healing is a complex physiological process
that involves a well-orchestrated series of biological
events, including inflammation, intramembranous ossifi-
cation, chondrogenesis, endochondral ossification, and
remodeling [3, 4]. This process can be divided into three
overlapping phases: inflammation, repair, and remodel-
ing. In the current study, the time point of post-fracture
day 14 was selected for microarray analysis because this
day is representative of key cellular events in rat fracture
healing. Post-fracture day 14 corresponds to the repair
phase, which is recognized as a time point representing
both soft and hard callus formation, including both
intramembranous and endochondral ossification [3, 4].
We then analyzed the dynamic expression patterns of
the five most highly expressed miRNAs selected, from
the microarray data, using real-time PCR on days 3, 7,
10, 14, 21, and 28. These time points were selected to rep-
resent specific physiological events during fracture healing,
including inflammation, angiogenesis, chondrogenesis, and
ossification, which corresponds to the inflammation phase
to the end of the reparative phase [15, 19, 20]. As atrophic
nonunion is established at 8 weeks after surgery in our
Fig. 3 Expression of miR-140-3p (a), miR-140-5p (b), miR-181a-5p (c), miR-181d-5p (d), and miR-451a (e) in standard healing fractures (solid bars)
and in unhealing fractures (blank bars) on post-fracture days 3 and 7, as analyzed by real-time PCR. All graphs show the fold change in expression
when expression in the standard healing fracture on day 3 was normalized as 1. Values are the mean ± standard error (n = 5 in each group at
each time point)
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unhealing fracture model [15], it would be interesting to
compare the expression levels of the selected miRNAs be-
tween standard healing fractures and unhealing fractures
and investigate their time-course changes at later time
points such as weeks 6 and 8. In future studies, we will in-
vestigate their expression levels at later time points.
Of the five identified miRNAs, miR-140-3p, miR-181a-
5p, and miR-451a have been reported to be involved in
the regulation of inflammatory responses (Table 2). In-
flammation is a critical factor during fracture healing,
with inflammatory cells and molecular factors appearing
locally at the fracture site in a distinct spatial and tem-
poral manner [21]. During the initial inflammatory phase
of fracture healing, inflammatory cells are rapidly recruited
to the site of injury, neutrophils being the first cells to in-
vade, followed by macrophages and lymphocytes. During
the repair phase, osteal macrophages, which are present
on the endosteal and periosteal surfaces, are pivotal for
intramembranous ossification, whereas inflammatory
macrophages recruited to a fracture site contribute to
endochondral ossification. Highly-regulated inflamma-
tory signaling during fracture healing is essential for
priming bone regeneration. Disturbance to the finely-
tuned inflammatory responses at the site of fracture has
been shown to impair vascularization, reduce bone for-
mation, disturb osteoclastic function, and consequently,
lead to nonunions [21].
miR-140-3p negatively regulates nuclear factor-κB (NF-
κB) inflammatory signaling by regulating the expression of
nuclear receptor coactivator 1 (NCOA1) and nuclear
receptor-interacting protein 1 (NRIP1), both of which are
NF-κB coactivators [22]. One of the primary molecular re-
sponses to tumor necrosis factor (TNF)-α signaling is acti-
vation of NF-κB [23]. In contrast, miR-181a-5p regulates
inflammatory responses by directly targeting and down-
regulating interleukin (IL)-1a [24]. Kon et al. demonstrated
that in a mouse model of fracture healing, expression
levels of TNF-α and IL-1a exhibited peaks in the inflam-
matory phase, declined to undetectable levels during the
repair phase, and increased again in the remodeling phase
[25]. This biphasic pattern is opposite to the monophasic
expression pattern of miR-140-3p and miR-181a-5p ob-
served in our study where the expression levels peaked in
the repair phase (Fig. 2a, c), indicating that miR-140-3p
and miR-181a-5p may suppress the expression of TNF-α
and IL-1a, respectively, in the repair phase.
miR-451a reduces inflammation by suppressing phos-
phorylation of p38 mitogen activated protein kinase
(MAPK) via 14-3-3ζ and Rab5a (Table 2) [26]. p38 MAPK
plays an important signaling role in orchestrating injury or
stress-induced responses and in bone formation [27]. Pro-
inflammatory cytokines, such as TNF-α and IL-1a, activate
p38 MAPK. In addition, activation and signaling of p38
MAPK also lead to the production of these inflammatory
cytokines and their signal transduction. The interaction
between p38 MAPK and pro-inflammatory cytokines is
important in controlling life and death signaling cascades
in osteoblasts and chondrocytes. Taken together, miR-140-
3p, miR-181a-5p, and miR-451a may play important roles
during fracture healing via the regulation of inflammation.
The process of fracture healing closely resembles normal
skeletal development, which occurs by intramembranous
and endochondral ossification [28]. Of the five identified
miRNAs, miR-140-5p, miR-181a-5p, miR-181d-5p, and
miR-451a have been reported to be involved in the regula-
tion of skeletal development (Table 2). miR-140-5p is
abundantly expressed in cartilaginous tissues during em-
bryogenesis and also in adult cartilage [9]. Nakamura et al.
demonstrated that miR-140-5p plays an essential role in
skeletal development by regulating processes of endochon-
dral ossification [29]. They identified Dnpep as a miR-140-
5p target gene whose up-regulation plays a causal role in
the skeletal defects of MiR-140-null mice by reducing
BMP signaling.
miR-181a-5p and miR-181d-5p target B-cell lymphoma-2
(Bcl-2) [30, 31]. Bcl-2 proteins are family of cytosolic pro-
teins involved in apoptotic pathways and regulate the
“mitochondrial” pathway to apoptosis. Bcl-2 has been re-
ported to be directly involved and required for skeletal
development [32]. Bcl-2 is involved in the regulation of the
programmed cell death of hypertrophic chondrocytes in
the growth plate, an event that is critical for endochondral
ossification. Furthermore, using osteoblast-specific Bcl-
2 transgenic mice, Moriishi et al. demonstrated that
over-expression of Bcl-2 in osteoblasts inhibits their dif-
ferentiation and induces osteocyte apoptosis [33]. Bhushan
et al. demonstrated that miR-181a-5p was induced during
different stages of mouse calvarial and tibial development,
indicating a role in both endochondral and intramembra-
nous ossification [34]. This study also demonstrated that
miR-181a-5p promotes osteoblastic differentiation via re-
pression of transforming growth factor-β (TGF-β) signal-
ing molecules by targeting the negative regulators of
osteoblastic differentiation, TGF-β-induced (TGFBI) and
TGF-β type I receptor (TβR-I).
Table 2 Validated target genes of the five up-regulated miRNAs




















NCOA1, nuclear receptor coactivator 1; NRIP1, nuclear receptor-interacting
protein 1; Dnpep, aspartyl aminopeptidase; IL-1a, interleukin-1 alpha; Bcl-2,
B-cell lymphoma-2; TGFBI, TGF-β-induced; TβR-I, TGF-β type I receptor;
CUGBP2, CUG triplet repeat-binding protein 2
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Finally, miR-451a targets CUG triplet repeat-binding
protein 2 (CUGBP2), an RNA-binding protein that inter-
acts with COX-2 mRNA 3′-UTR and inhibits its transla-
tion [35]. Up-regulation of miR-451a down-regulates
CUGBP2, thereby significantly increasing COX2 protein
levels. COX2 acts as a stress response and is responsible
for high levels of prostaglandin production during inflam-
mation. COX2 is an important factor partaking in chon-
drocyte hypertrophy during endochondral ossification in
skeletal development [36]. In addition, COX2 is a critical
regulator of fracture healing in animal models [37, 38].
Xie et al. showed that COX2 expression peaks at the early
stages of intramembranous and endochondral repair, and
is subsequently reduced during the remodeling phase [37].
Fractures in Cox2−/− mice are deficient in reparative bone
formation and exhibit persistent undifferentiated mesen-
chyme, suggesting that COX2 is necessary for normal
fracture healing [38]. Zhang et al. concluded that COX2
was required for both intramembranous and endochon-
dral ossification during fracture healing [38]. Collectively,
these four miRNAs, namely miR-140-5p, miR-181a-5p,
miR-181d-5p, and miR-451a, may play important roles
during fracture healing by regulating intramembranous
and/or endochondral ossification.
The present results have clinical implications. Fractures
with high-energy injury, such as the presence of commin-
ution, open fractures, massive bone defects, severe soft tis-
sue damage, and local blood supply damage are at high
risk of delayed union or nonunion [39]. Many biological
and biophysical interventions have been used to attempt
acceleration of fracture healing in such cases, including
the use of exogenous growth factors, such as bone mor-
phogenetic proteins, low-intensity pulsed ultrasound, and
stem/progenitor cell transplantation [40–42]. Although
most of these strategies exhibit relatively satisfactory re-
sults, there are some notable limitations to their effective-
ness and availability. The recent discovery of miRNAs and
their ability to regulate global gene expression patterns in
a variety of tissues and processes suggests potential thera-
peutic strategies involving targeting of miRNAs. Several
therapeutic trials targeting miRNAs have been conducted
[43]. Recently, Miravirsen (SPC3649) entered human clin-
ical trials for the treatment of hepatitis C virus (HCV) in-
fection as the first miRNA-targeted drug. Janssen et al.
reported phase 2a clinical trial results showing that Mira-
virsen, which sequesters miR-122, dose-dependently and
sustainably decreased HCV RNA levels in patients with
chronic HCV infection [44]. The miRNAs identified in the
current study might represent key tools for the develop-
ment of molecular therapies to enhance fracture healing.
For example, in fracture patients at high risk for delayed
union or nonunion, local administration of synthesized
miRNA oligonucleotides to the fracture site may acceler-
ate fracture healing. However, further in vivo functional
analyses will be required to define the precise role of each
miRNA during fracture healing.
Conclusions
The five miRNAs, miR-140-3p, miR-140-5p, miR-181a-
5p, miR-181d-5p, and miR-451a, identified using micro-
array and real-time PCR analyses may play important
roles during fracture healing. Our findings provide valu-
able information to further understand the molecular
mechanisms of fracture healing and may lead to the de-
velopment of miRNA-based tissue engineering strategies
to promote fracture healing and bone regeneration.
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